The Efficacy of Adductor-Canal-Block (ACB) in Patients After Knee Arthroscopy

Phase 4

Completed

• Conditions: Meniscus Lesion; Pain (Knee); Diagnostic Knee Artroscopy; Minor Knee Surgery
• Interventions: Procedure: Adductor-Canal-Block, Ropivacain; Procedure: Adductor Canal Block, Placebo (saline)

• Registration Number: NCT01254825
• Lead Sponsor: Glostrup University Hospital, Copenhagen

Brief Summary

The Purpose of this study is to determine whether Adductor-Canal-Block (ACB) is superior to placebo when it comes to analgetic efficacy after Knee-Arthroscopy.

Detailed Description

Not available

Study Timeline

• Study Start: 2010-11
• Study First Submitted: 2010-12-06
• Study First Submitted QC: 2010-12-06
• Study First Posted: 2010-12-07
• Primary Completion: 2011-09
• Study Completion: 2011-09
• Status Verified: 2012-09
• Last Update Submitted: 2012-09-09
• Last Update Posted: 2012-09-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 72

Inclusion Criteria

• 18-80 years
• Knee-arthroscopy
• Written consent
• ASA I-III
• BMI 19-35

Exclusion Criteria

• Unable to communicate in Danish
• Allergic reactions toward drugs used in the trial
• Pregnancy
• Abuse of alcohol/drugs
• Daily opioid intake
• Infection at injection site
• Can not be mobilised to 5 meters of walk; pre-surgery

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Adductor-Canal-Block, Ropivacain	Adductor-Canal-Block, Ropivacain	Adductor-Canal-Block, 30 mL Ropivacain 7,5 mg/mL. Single dose. Ultrasound-guided application. 36 patients
Adductor-Canal-Block (ACB) - Saline	Adductor Canal Block, Placebo (saline)	Adductor-Canal-Block, Placebo (30 mL Saline). Ultrasound-guided application. 36 patients.

Primary Outcome Measures

Name	Time	Method
Pain-Score (VAS) - patient standing	2 hours postoperative	Pain-score messured on a Visual Analog Scale (VAS) 2 hours after adductor canal block. Patient standing. Intervention-group vs. placebo-group.

Secondary Outcome Measures

Name	Time	Method
Pain-score (VAS), patient at rest	0,1,2,4,6,8,24 hours postoperative	ACB-group vs. placebo
Pain-score (VAS), patient standing	1,2,4,6,8,24 hours postoperative	ACB-group vs. placebo
Pain-score (VAS), after 5 meters of walk	2,4,6,8,24 hours postoperative	ACB-group vs. placebo
Total Opioid-consumption	0-24 hours postoperative	ACB-group vs. placebo-group
Opioid-consumption, postoperative	0-2, 2-4, 4-6, 6-8, 8-24 hours postoperative	i.v. morfin 0-2 hours postoperative tbl. morfin 2-24 hours postoperative ACB vs. placebo
Postoperative Nausea and vomiting	0-1, 1-2, 2-4, 4-6, 6-8, 8-24 hours postoperative	Rating-scale 0-3 ACB-group vs. placebo-group
Postoperative ondansetron consumption	In-hospital	ACB-group vs. placebo-group
Sedation	0,1,2,4,6,8,24 hours postoperative	Rating-scale: 0-3 ACB-group vs. placebo-group

Trial Locations

Locations (1)

Department of Anaesthesiology, Glostrup University Hospital; 🇩🇰 Glostrup, Copenhagen, Denmark